Recognify Life Sciences to Commence Phase 2a Study in Cognitive Impairment Associated with Schizophrenia

Written By ATAI

Recognify Life Sciences, an atai Life Sciences platform company focused on developing treatments for cognitive impairment with initial efforts targeting Cognitive Impairment Associated with Schizophrenia (CIAS), today announced it has initiated a Phase 2a study for its lead compound RL-007, after receiving IND clearance from the Food and Drug Administration to commence clinical trials in the United States in this indication.

Read more

ATAI
Previous

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia
Next

atai Life Sciences Acquires Majority Stake in Recognify Life Sciences to Develop Novel Treatment for Cognitive Impairment Associated with Schizophrenia